JP2021530453A5 - - Google Patents
Info
- Publication number
- JP2021530453A5 JP2021530453A5 JP2020571855A JP2020571855A JP2021530453A5 JP 2021530453 A5 JP2021530453 A5 JP 2021530453A5 JP 2020571855 A JP2020571855 A JP 2020571855A JP 2020571855 A JP2020571855 A JP 2020571855A JP 2021530453 A5 JP2021530453 A5 JP 2021530453A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutically acceptable
- pharmaceutical composition
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126807A JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692176P | 2018-06-29 | 2018-06-29 | |
| US62/692,176 | 2018-06-29 | ||
| PCT/US2019/039509 WO2020006233A1 (en) | 2018-06-29 | 2019-06-27 | Immunomodulatory compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126807A Division JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530453A JP2021530453A (ja) | 2021-11-11 |
| JP2021530453A5 true JP2021530453A5 (https=) | 2022-07-05 |
| JP7328263B2 JP7328263B2 (ja) | 2023-08-16 |
Family
ID=68987232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571855A Active JP7328263B2 (ja) | 2018-06-29 | 2019-06-27 | 免疫調節化合物 |
| JP2023126807A Pending JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126807A Pending JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12234220B2 (https=) |
| EP (1) | EP3814330A4 (https=) |
| JP (2) | JP7328263B2 (https=) |
| KR (1) | KR102834593B1 (https=) |
| CN (1) | CN113166100A (https=) |
| AU (1) | AU2019293235B2 (https=) |
| CA (1) | CA3102212A1 (https=) |
| WO (1) | WO2020006233A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118108706A (zh) * | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| EP3814330A4 (en) * | 2018-06-29 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| JP7852923B2 (ja) * | 2019-11-27 | 2026-04-28 | キャプター セラピューティクス エス．エー． | セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法 |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022255889A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| CN116655595A (zh) * | 2023-06-05 | 2023-08-29 | 中国人民解放军军事科学院军事医学研究院 | 2,6-哌啶二酮衍生物及其制备和用途 |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| WO2008007979A1 (en) * | 2006-07-12 | 2008-01-17 | Auckland Uniservices Limited | (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
| BR112018068906A2 (pt) * | 2016-03-16 | 2019-01-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| EP3814330A4 (en) * | 2018-06-29 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
-
2019
- 2019-06-27 EP EP19826640.5A patent/EP3814330A4/en active Pending
- 2019-06-27 JP JP2020571855A patent/JP7328263B2/ja active Active
- 2019-06-27 CA CA3102212A patent/CA3102212A1/en active Pending
- 2019-06-27 WO PCT/US2019/039509 patent/WO2020006233A1/en not_active Ceased
- 2019-06-27 KR KR1020217002635A patent/KR102834593B1/ko active Active
- 2019-06-27 US US17/255,738 patent/US12234220B2/en active Active
- 2019-06-27 CN CN201980056905.1A patent/CN113166100A/zh active Pending
- 2019-06-27 AU AU2019293235A patent/AU2019293235B2/en active Active
-
2023
- 2023-08-03 JP JP2023126807A patent/JP2023145694A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530453A5 (https=) | ||
| JP2021530451A5 (https=) | ||
| JP2021191784A5 (https=) | ||
| JP2019094340A5 (https=) | ||
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| JP2023523130A5 (https=) | ||
| CN113748114A (zh) | 一种喹唑啉化合物及其在医药上的应用 | |
| JP2020511467A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2022538215A5 (https=) | ||
| JP2013519675A5 (https=) | ||
| JP2015078230A5 (https=) | ||
| JP2013509429A5 (https=) | ||
| JP2016522266A5 (https=) | ||
| JP2021535147A5 (https=) | ||
| JP2013522326A5 (https=) | ||
| JP2022515293A5 (https=) | ||
| JP2019520343A5 (https=) | ||
| JP2021530487A5 (https=) | ||
| RU2018144755A (ru) | Соединения для стимуляции роста волос и/или ингибирования или замедления выпадения волос у человека и композиции для их применения | |
| JP2024512425A5 (https=) | ||
| RU2016136193A (ru) | Аминокарбонилкарбаматные соединения | |
| JP2021525752A5 (https=) | ||
| JP2020504156A5 (https=) | ||
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها |